Fig 1: PP2Acα ablation inhibits macrophage migration by suppressing Rap1.a, b Representative images (a) and quantitative analysis (b) for wound healing test in cultured BMDMs. Scale bar, 100 μm. *p < 0.05, n = 6. Data are presented as means ± SEM. c, d Representative images (c) and quantitative analysis (d) for cell spreading in cultured BMDMs. Scale bar, 10 μm. *p < 0.05, n = 4. Data are presented as means ± SEM. e Immunoprecipitation assay showing the induction of serine/threonine phosphorylation of Rap1a/b in PP2Acα−/− BMDMs. f Graphic presentation showing the activity of Rap1a/b in PP2Acα+/+ and PP2Acα−/− BMDMs. *p < 0.05, n = 5. Data are presented as means ± SEM. g Western blot analyses showing the reduction of Rap1a/b in PP2Acα−/− BMDMs. h Representative immune staining images for Rap1a/b in PP2Acα+/+ and PP2Acα−/− BMDMs. Scale bar, 100 μm. i, j Representative images (i) and quantitative analysis (j) for wound healing test in cultured BMDMs from different groups as indicated. Scale bar, 100 μm. *p < 0.05, n = 3. #p < 0.05, n = 3. Data are presented as means ± SEM. k Immunoprecipitation assay showing the binding of Rap1a/b and Itgb2 in BMDMs. l Representative immune staining images showing the clustering of Itgb2 in PP2Acα+/+ and PP2Acα−/− BMDMs cultured on the plate coated with fibronectin. White arrows indicate Itgb2 clustering. Scale bar, 10 μm. m Real-time qRT-PCR analysis showing the mRNA abundance of Itgb2 in scramble siRNA and Itgb2 siRNA-transfected BMDMs. *p < 0.05, n = 3. Data are presented as means ± SEM. n, o Representative images (n) and quantitative analysis (o) for wound healing test in cultured BMDMs from different groups as indicated. Scale bar, 100 μm. *p < 0.05, n = 3. #p < 0.05, n = 3. Data are presented as means ± SEM.
Fig 2: C3 alternative pathway components expression in human VSMCs. (A) mRNA quantification by real-time PCR using specific primers for human C3 in human VSMCs treated with or without agLDL (100 µg/mL). (B) Protein levels of C3 and C3-derived products in the supernatant of hVSMCs treated with or without agLDL (100 µg/mL). Human serum (Serum) was used as a positive control for C3 (n = 3 independent experiments). (C) Western blot analysis for C3a receptor (C3aR) and αMβ2 (C11b/CD18) integrin (receptor for C3b/iC3b) in lysates of hVSMCs incubated with or without agLDL (100 µg/mL). Band intensity is given in arbitrary units as mean ± SEM and statistical significance (p < 0.05, Mann–Whitney test) is indicated (n = 4 independent experiments).
Supplier Page from Abcam for Anti-CD18 antibody [M18/2]